Abstract
INTRODUCTION
Lenvatinib (Lenvima®, LEN) is an orally bioavailable multitarget tyrosine kinase inhibitor (TKI), acting on VEGFR, FGFR, PDGFR-α, KIT and RET. [1] To date, LEN is licensed for advanced progressive radioactive-iodine (RAI) refractory differentiated thyroid cancer (DTC) patients [2] . It has also been approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA), in combination with everolimus, as second-line in advanced renal cell carcinoma (RCC) [3] . Recently, FDA has recently approved LEN as first-line therapy in advanced hepatocellular carcinoma (HCC) considering the results of non-inferiority (versus sorafenib) phase III trial (REFLECT) [4] .
Moreover, LEN has already been studied as monotherapy [5] and in combination with immunotherapy (pembrolizumab) [6] in renal cell carcinoma, in metastatic or recurrent endometrial cancer (EC) [5] and in anaplastic thyroid cancer (ATC) [7] . The results of a single-Institution phase II study with LEN in advanced adenoid cystic carcinoma (ACC) of salivary glands will be published in the near future since recruitment has already been completed [8] . Table 1 summarized all ongoing clinical trials evaluating LEN in several other malignancies.
In brief, in the era of targeted therapies, LEN is is one of the most promising targeted agents with multiple opportunities of application in the clinical practice.
CASE REPORTS
Here, we report two cases of LEN-induced renal failure (LIRF).
These two reports gave us the opportunity to review, understand and discuss pathogenesis of LIRF in order to better manage this toxicity. Both cases were reported to the Italian network of pharmacovigilance [9] .
Informed consent forms were collected.
CASE 1

CLINICAL HISTORY
In 1998 a papillary thyroid carcinoma was diagnosed in a 44-year-old man, with arterial hypertension (AH) as only comorbidity (AH managed by doxazosin 2 mg, atenolol 25 mg and chlorthalidone 6.25 mg per day).
He underwent total thyroidectomy (stage pT2a, cN0 cM0 according to seventh edition of AJCC TNM), post- proteinuria (1+ at urine dipstick). Proteinuria was managed as per protocol: if proteinuria was ≥2+ at urine dipstick, a 24-hour proteinuria was evaluated within 72 hours without LEN interruption; in case of proteinuria lower than 1 g/24h (≤ grade 1 CTCAE) the drug was continued, otherwise LEN was discontinued until toxicity was resolved to grade 0-1 or baseline and reduced at lower level dose when resumed. Figure 1 summarized a time-dependent overview of LEN management (e.g. all temporary discontinuations and dose reductions to 20, 14 and 10 mg/day at 6 th , 10 th and 36 th treatment month, respectively) based on the evolution of serum creatinine and proteinuria. Concomitantly, a persistent disease control was achieved after a partial remission, occurred as best response at 2 nd month of LEN course. Considering this significant clinical benefit and that baseline proteinuria was abnormal (grade 1) remaining stable (2+ at urine dipstick)
for one year of treatment (with no further AEs), an agreement with study Sponsor (Eisai) was established.
This consisted of performing 24-hour proteinuria only in case of 3+ at urine dipstick. At the fourth year of LEN, proteinuria worsened (G3, >3.5g/24h according to CTCAE), with significant increase of AH (G3, 160/80 mmHg) and serum creatinine (G1, 1.9 mg/dl), so LEN was interrupted and patient was hospitalized. Due to the persistence of lab tests abnormalities after 10 days of LEN discontinuation (half-life of LEN is approximately 28 hours), a kidney biopsy was performed in order to exclude all possible other causes of renal failure (RF). So, a complex pattern of drug-related glomerular, tubulointerstitial, and vascular renal A c c e p t e d M a n u s c r i p t injury was diagnosed (Figures 2 and 3) . Histological details will be reported in the next paragraph. After the start of angiotensin converting enzyme (ACE) inhibitor, blood pressure values were normalized while proteinuria (G1) and serum creatinine significantly decreased (G1, 1.68 mg/dl) within further 4 weeks.
LEN was definitively stopped and patient went on clinical and radiological follow-up every 4-6 months.
Following lab tests showed chronic kidney damage (serum creatinine ranging from 1.4 to 1.6 mg/dl and proteinuria 1+ to 2+ at urine dipstick).
HISTOLOGICAL FINDINGS
For the histological analysis, kidney biopsy was fixed in 10% buffered formalin and embedded in paraffin.
Specific staining for renal tissue was performed. A second specimen was snap-frozen and used for immunefluorescence analysis. A third sample (5 mm) was fixed in 2.5% glutaraldehyde, embedded in resin and reserved for electron microscopy. Semi-thin and thin sections were cut and stained using conventional methods. Tissues were then examined by transmission electron microscopy (Zeiss EM109 electron microscope).
Light microscopy examination revealed a huge number (n=24) of glomeruli, whose 45% (n=11) were Immune-fluorescence analysis revealed weak focal and segmental staining for immunoglobulins and complement along the capillary basal membrane.
Ultrastructural examination (Figure 3) showed focal glomerular sclerosis, focal podocyte foot process effacement and rare electron dense deposits with subendothelial and intramembranous localization.
The diagnosis concluded for a drug-induced renal damage characterized by tubulointerstitial vascular necrotic injury and endothelial alterations suggesting for a thrombotic microangiopathy (TMA)-like pattern with ultrastructural evidence of podocytes foot process effacement.
CASE 2 2.2.1 CLINICAL HISTORY
In 2015 a 59-year-old woman, without significant cardiologic or pneumologic comorbidities (no conocomitant medications at baseline), started her clinical history suffering of steroid-resistant mild dyspnea. A fiber optic bronchoscopy showed a subtotal occlusion of the medium third part of the trachea 
REVIEW
LENVATINIB-INDUCED RENAL FAILURE (LIRF) AND PROTEINURIA
Data coming from the only LEN pivotal trials already published as full-papers [2] [3] showed a complex safety profile for this drug. As illustrated in Table 2 , in both trials almost 100% and 75% of patients experienced at least one any-grade (AG) and grade 3 (G3) treatment-related adverse events (TRAE),
respectively. This led to frequent drug discontinuations and/or dose reductions, thus impairing the LEN exposition and potentially patient outcomes. Indeed, a clear-cut relationship between drug exposure and anticancer activity has already been well described for multikinase inhibitors Sunitinib and Sorafenib. [10, 11] .
In the pivotal trial of LEN in RAI-refractory metastatic and progressive DTC (SELECT study) [2] , proteinuria was one of the most frequent TRAEs, resulting as the second one (10%) among ≥G3 TRAEs (after AH, 41.8%) and the third cause (18.8%) of drug interruptions and/or reductions after diarrhea (22.6%) and AH (19.9%). In a subgroup analysis of SELECT trial, including elderly patients (> 65 years) [11] , a higher incidence of G3 TRAEs, especially including AH and proteinuria, was reported in elderly (88.7%) versus younger (≤ 65 years) DTC patients (67.1%), thus leading to a shorter time (1.5 vs 3.7 months, respectively) elapsed before the first dose reduction.
Proteinuria was the most frequent G3 TRAE when LEN has been studied as monotherapy in RCC patients (19%), compared to combination of LEN plus everolimus (4%) and everolimuns alone (2%) [3] .
In the phase II trial of LEN in HCC [12], proteinuria was the most frequent cause of study drug withdrawal (11%). [3] .
The subgroup analysis of elderly (> 65 years) in SELECT trial [11] confirmed this trend for G3 proteinuria (13.2%) when compared to that observed (7.7%) in younger patients (≤ 65 years).
In addition to age, further pre-existing risk factors of RF induction were identified: AH, stage≥3 chronic kidney disease (CKD), TMA, and all grade proteinuria [14] .
A c c e p t e d M a n u s c r i p t Starting from a phase I study, Keizer et al. structured a pharmacokinetic-pharmacodynamic model for AH and proteinuria. In this work they showed that both lenvatinib plasma concentration and an increased diastolic blood pressure have a separate effect on the development of proteinuria.
[17]
FGF/FGFR PATHWAY INHIBITION
Other molecular targets could also explain LIRF. Among them, the FGF/FGFRs pathway blockade has to be cited, though controversial evidences are available; indeed, in vitro, FGF23 proved to exert divergent effects on fibroblast activation in cells derived from normal and obstructed kidneys. While FGF23 failed to stimulate fibrogenesis in normal fibroblasts, in those primed by injury, FGF23 induced pro-fibrotic signaling cascades via activation of TGF-β pathways. Tubule-derived FGF23 may thus amplify myofibroblast activation in acute renal injury, leading to renal fibrosis and injury [18] .
Having said that, because FGF/FGFR is not targeted by other antiangiogenic drugs, VEGF/VEGFR axis inhibition has to be considered the key mechanism in inducing RF.
A c c e p t e d M a n u s c r i p t
CONCLUSION
We described two cases of LIRF with alternative clinical and pathogenetic patterns.
In both reports, further causes of renal damage, such as concomitant nephrotoxic medications, co-existing autoimmune syndromes, infections and any other renal disorder, were excluded.
In case 1, a glomerular drug injury with secondary proteinuria and indirect tubulointerstitial damage was observed and histologically characterized. Potentially, this represented a spurious (with only kidney disease) TMA-like pattern induced byVEGF/VEGFRs pathway inhibition.
In case 2, the kidney damage was mainly based on a direct tubular failure, without proteinuria and glomerular involvement. A possible tubulointerstitial nephritis was clinically diagnosed. This hypothesis was also supported by the ex juvantibus effect yielded using corticosteroids.
The putative pathogenetic mechanism presented in case 2 could open the way to a completely different diagnostic and therapeutic approach, based on chronic low-dose steroids use.
EXPERT OPINION
Acute or chronic renal function deficiency, regardless of its drug-related pathogenesis is based on a damage of renal tubuli. That is the reason why any primary glomerular injury, with secondary proteinuria, is rarely linked to RF, as it needs longer time to induce tubular alterations. This is the classical way throughout the most part of antiangiogenic agents, as LEN, might lead to renal disorders. Therefore, tubulointerstitial RF is underestimated compared to proteinuria [15] . Notably, in case 1, proteinuria needed almost four years to induce an acute RF. Moreover, in the literature [8], Brose et al also described renal toxicities as the most frequent LEN AEs (after AH) among elderly (> 65 years) thyroid cancer patients.
The renal side effects from TKIs have already been described, and the first multicentric experiences of LIRF in DTC as well [2] . However, to the best of our knowledge, this work reports the histological features of LIRF for the first time.
In case 1, mesangiolysis is very rare and usually lacking in primary glomerular nephropaties, except for those observed in diabetes and hemolytic uremic syndrome (both excluded in our patient) or in case of some cytotoxic chemotherapy-induced kidney injury (e.g. Mitomycin-C) [19] . Concomitantly, LEN-induced endothelial alterations, notably hypertrophy, determine severe vascular injury, configuring a TMA-like pattern, similarly to that observed in the kidney injury caused by other antiangiogenics.
In this drugs class, the classical histopathological picture is characterized by glomerular endotheliosis, focal segmental glomerulosclerosis (sometimes collapsing), various glomerulopathies, and most commonly TMA [20] , with few cases of acute interstitial nephritis.
A c c e p t e d M a n u s c r i p t
With regards to the medical treatment of TKIs induced proteinuria, no standardized guidelines are available. Nevertheless, many papers reported the activity of ACE inhibitors in this setting [21] . In fact, the rationale to use this drugs class is the prevention of both AH and cardiovascular events [22] .In case 2, a direct tubulointerstitial damage, without glomerular involvement and proteinuria development, was
hypothesized. This type of injury was described for almost all antiangiogenics (e.g. Bevacizumab, Sorafenib, Sunitinib [23]), but it has never been reported with LEN.
The time needed to be elapsed before LIRF induction was significantly shorter in case 2 (14 months) than what observed in case 1 (42 months) due to the intrinsic LIRF mechanisms explained. However, in both reports, timing remains as one of the most important variables, together with the presence or not of proteinuria, to differentiate these two models of LIRF.
The weakness of case 2 was the lack of the histological confirmation: all conclusions were based only on the clinical results (blood and urinary tests) and no kidney biopsy was performed to avoid patient an invasive diagnostic approach. Moreover, apart from interstitial nephritis, a relevant number of glomerular abnormalities, like glomerulosclerosis, can respond to corticosteroid therapy. Our diagnosis of interstitial nephritis may be also less consistent due to the absence of both eosinophiluria and eosinophilia in our patient. With these caveats, in case of LIRF without proteinuria, low doses of steroids shoud be considered in order to avoid kidney biopsy and carry on with an active anti-tumor agent. In fact, an inflammatory component is very likely in TKI-induced renal damage.
Regardless of these limitations, the identification of different pathogenetic LIRF mechanisms could have a key relevance in optimizing the diagnostic and therapeutic strategies. Indeed, for example in case of a LIRF pattern characterized by G2 proteinuria (24-hour urine), such as in case 1, one could speculate to temporarily stop and reduce LEN after recovery from toxicity. This could be suggested because proteinuria tends to resolve with drug withdrawal. For this reason, proteinuria should be always assessed in patients under treatment with LEN and the management of LEN-induced proteinuria could be the same of that caused by bevacizumab [24] .
On the other hand, an acute kidney injury secondary to a possible interstitial nephritis could often lead to treatment discontinuation due to its trend to a rapid relapse, as demonstrated in case 2. In this alternative LIRF model, patients can benefit of chronic low-dose steroids without any drug interruption and/or dose reduction. The latter aspect is particularly relevant to optimize drug exposition.
Therefore, it is intuitive that better understanding LIRF mechanisms may lead to a such promptness in discovering or preventing RF, thus improving drug efficacy and safety. Notably, saving toxicities deserves to be considered in long-term survivor cancer patients, like those here reported.
A c c e p t e d M a n u s c r i p t M a n u s c r i p t Table 3 -Incidence of any CTCAE grade and grade≥3 Lenvatinib-induced renal failure and proteinuria in Medical Oncology *Underestimated because of urine analysis was not done as routine test in study patients.
Abbreviations (in alphabetical order):
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